share_log

Koshinski Asset Management Inc. Trims Stock Position in ShockWave Medical, Inc. (NASDAQ:SWAV)

Koshinski Asset Management Inc. Trims Stock Position in ShockWave Medical, Inc. (NASDAQ:SWAV)

科辛斯基資產管理公司調整衝擊波醫療公司的股票頭寸(納斯達克代碼：SWAV)
Defense World ·  2022/09/24 06:21

Koshinski Asset Management Inc. lessened its holdings in shares of ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,365 shares of the company's stock after selling 115 shares during the period. Koshinski Asset Management Inc.'s holdings in ShockWave Medical were worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

根據科辛斯基資產管理公司在提交給美國證券交易委員會(美國證券交易委員會)的最新Form 13F文件中的説法，該公司在第二季度減持了ShockWave Medical，Inc.的股票7.8%。該基金在此期間出售了115股後，持有1,365股該公司股票。截至最近提交給美國證券交易委員會(Securities and Exchange Commission，美國證券交易委員會)的文件，科辛斯基資產管理公司持有的Shockwave Medical股份價值261,000美元。

Other institutional investors have also recently made changes to their positions in the company. Lincoln National Corp purchased a new position in shares of ShockWave Medical during the first quarter worth $211,000. Level Four Advisory Services LLC grew its position in ShockWave Medical by 21.2% during the first quarter. Level Four Advisory Services LLC now owns 4,426 shares of the company's stock valued at $918,000 after buying an additional 773 shares during the period. Wealth Dimensions Group Ltd. acquired a new stake in ShockWave Medical during the first quarter valued at $207,000. HM Payson & Co. acquired a new stake in ShockWave Medical during the fourth quarter valued at $77,000. Finally, Avestar Capital LLC acquired a new stake in ShockWave Medical during the first quarter valued at $413,000. Hedge funds and other institutional investors own 95.40% of the company's stock.

其他機構投資者最近也對他們在該公司的頭寸進行了調整。林肯國家公司在第一季度購買了ShockWave Medical的新頭寸，價值211,000美元。Level Four Consulting Services LLC在第一季度將其在Shockwave Medical的頭寸增加了21.2%。Level Four Consulting Services LLC現在擁有4426股該公司的股票，價值91.8萬美元，在此期間又購買了773股。財富維度集團有限公司在第一季度收購了Shockwave Medical的新股份，價值20.7萬美元。HM Payson&Co.在第四季度以77,000美元的價格收購了Shockwave Medical的新股份。最後，Avestar Capital LLC在第一季度收購了ShockWave Medical的新股份，價值41.3萬美元。對衝基金和其他機構投資者持有該公司95.40%的股票。

Get
到達
ShockWave Medical
衝擊波醫療
alerts:
警報：

Analyst Upgrades and Downgrades

分析師升級和下調評級

SWAV has been the topic of several analyst reports. Morgan Stanley raised their price target on shares of ShockWave Medical from $201.00 to $255.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 9th. Oppenheimer lowered shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price target on the stock. in a research report on Tuesday, September 6th. Wells Fargo & Company raised their price target on shares of ShockWave Medical from $176.00 to $255.00 and gave the company an "overweight" rating in a research report on Tuesday, August 9th. Piper Sandler lifted their target price on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an "overweight" rating in a research report on Monday, August 29th. Finally, Canaccord Genuity Group lifted their target price on shares of ShockWave Medical from $232.00 to $256.00 and gave the company a "buy" rating in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $246.50.

SWAV一直是幾份分析師報告的主題。8月9日，摩根士丹利在一份研究報告中將衝擊波醫療股份的目標價從201.00美元上調至255.00美元，並給予該公司“同等權重”的評級。奧本海默將Shockwave Medical的股票評級從“市場表現”下調至“表現不佳”，併為該股設定了165.00美元的目標價。在9月6日星期二的一份研究報告中。富國銀行將Shockwave Medical的股票目標價從176.00美元上調至255.00美元，並在8月9日週二的一份研究報告中給予該公司“增持”評級。8月29日，派珀·桑德勒在一份研究報告中將Shockwave Medical的股票目標價從278.00美元上調至338.00美元，並給予該公司“增持”評級。最後，Cancord Genuity集團在8月9日週二的一份研究報告中將Shockwave Medical的目標價從232.00美元上調至256.00美元，並給予該公司“買入”評級。一位股票研究分析師對該股的評級為賣出，一位分析師給出了持有評級，七位分析師給出了買入評級。根據MarketBeat.com的數據，該股目前的普遍評級為“中等買入”，平均目標價為246.50美元。

Insiders Place Their Bets

內部人士下注

In other ShockWave Medical news, insider Isaac Zacharias sold 4,000 shares of ShockWave Medical stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $198.00, for a total transaction of $792,000.00. Following the transaction, the insider now directly owns 78,563 shares of the company's stock, valued at $15,555,474. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through
在另一則Shockwave Medical新聞中，內部人士Isaac Zacharias在一筆日期為6月27日星期一的交易中出售了4,000股Shockwave Medical股票。這些股票以198.00美元的平均價格出售，總成交額為792,000.00美元。交易完成後，這位內部人士現在直接持有該公司78,563股股票，價值15,555,474美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
the SEC website
美國證券交易委員會網站
. In other ShockWave Medical news, insider Isaac Zacharias sold 4,000 shares of ShockWave Medical stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $198.00, for a total transaction of $792,000.00. Following the transaction, the insider now directly owns 78,563 shares of the company's stock, valued at $15,555,474. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through
。在另一則Shockwave Medical新聞中，內部人士Isaac Zacharias在一筆日期為6月27日星期一的交易中出售了4,000股Shockwave Medical股票。這些股票以198.00美元的平均價格出售，總成交額為792,000.00美元。交易完成後，這位內部人士現在直接持有該公司78,563股股票，價值15,555,474美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
the SEC website
美國證券交易委員會網站
. Also, VP Trinh Phung sold 3,500 shares of ShockWave Medical stock in a transaction dated Friday, August 26th. The stock was sold at an average price of $310.76, for a total transaction of $1,087,660.00. Following the transaction, the vice president now directly owns 25,063 shares in the company, valued at $7,788,577.88. The disclosure for this sale can be found
。此外，副總裁Trin h Phung在一筆日期為8月26日(星期五)的交易中出售了3500股Shockwave Medical股票。股票以310.76美元的平均價格出售，總成交金額為1,087,660.00美元。交易完成後，總裁副手現在直接持有該公司25,063股股份，價值7,788,577.88美元。關於這次銷售的披露可以找到
here
這裏
. Insiders have sold 108,700 shares of company stock valued at $30,247,696 over the last ninety days. Company insiders own 3.90% of the company's stock.
。在過去的90天裏，內部人士已經出售了108,700股公司股票，價值30,247,696美元。公司內部人士持有該公司3.90%的股份。

ShockWave Medical Stock Performance

衝擊波醫療類股表現

SWAV opened at $252.08 on Friday. The firm has a market capitalization of $9.02 billion, a PE ratio of 172.66 and a beta of 1.06. ShockWave Medical, Inc. has a twelve month low of $113.36 and a twelve month high of $314.90. The firm's 50-day moving average price is $264.51 and its 200 day moving average price is $208.82. The company has a current ratio of 5.32, a quick ratio of 4.41 and a debt-to-equity ratio of 0.02.

上週五，SWAV股開盤報252.08美元。該公司市值為90.2億美元，市盈率為172.66，貝塔係數為1.06.Shockwave Medical，Inc.的12個月低點為113.36美元，12個月高位為314.90美元。該公司的50日移動均線價格為264.51美元，200日移動均線價格為208.82美元。該公司的流動比率為5.32，速動比率為4.41，債務權益比率為0.02。

ShockWave Medical (NASDAQ:SWAV – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.68 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.25. The firm had revenue of $120.70 million for the quarter, compared to analyst estimates of $107.51 million. ShockWave Medical had a net margin of 15.11% and a return on equity of 21.25%. ShockWave Medical's quarterly revenue was up 115.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.01) earnings per share. As a group, sell-side analysts expect that ShockWave Medical, Inc. will post 2.57 EPS for the current fiscal year.

衝擊波醫療(納斯達克：SWAV-GET評級)最近一次公佈季度收益是在8月8日星期一。該公司公佈本季度每股收益為0.68美元，比分析師普遍預期的0.43美元高出0.25美元。該公司本季度營收為1.207億美元，而分析師預期為1.0751億美元。Shockwave Medical的淨利潤率為15.11%，股本回報率為21.25%。衝擊波醫療公司的季度收入同比增長了115.5%。去年同期，該業務公佈的每股收益為(0.01美元)。作為一個整體，賣方分析師預計Shockwave Medical，Inc.本財年每股收益將達到2.57美元。

About ShockWave Medical

關於衝擊波醫療

(Get Rating)

(獲取評級)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Shockwave Medical，Inc.是一家醫療設備公司，致力於開發和商業化血管內碎石技術，用於治療全球外周血管、冠狀動脈和心臟瓣膜疾病患者的鈣化斑塊。該公司提供用於治療膝關節以上外周動脈疾病(PAD)的M5導管；用於治療冠狀動脈疾病的C2導管；以及用於治療膝蓋以下PAD的S4導管。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免費獲取StockNews.com關於Shockwave Medical(SWAV)的研究報告
  • MarketBeat：回顧一週9/19-9/23
  • 為什麼特斯拉的股票保持彈性？
  • 小盤股的裁員是樓市的晴雨表嗎？
  • 需要關注的2只半導體類股走勢逆轉
  • 好市多盈利後價格疲軟是買入的好時機嗎？

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《衝擊波醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ShockWave Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論